Clinical severity of Alzheimer's disease is associated with PIB uptake in PET
暂无分享,去创建一个
Timo Grimmer | Hans Förstl | Gjermund Henriksen | Alexander Drzezga | Hans-Jürgen Wester | A. Drzezga | Hans Förstl | H. Wester | T. Grimmer | G. Henriksen
[1] Lisa A. Weissfeld,et al. Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease , 2006, NeuroImage.
[2] G. Small,et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[3] W. Klunk,et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.
[4] J. Morris,et al. Neuropathologic Criteria for Diagnosing Alzheimer Disease in Persons with Pure Dementia of Alzheimer Type , 2004, Journal of neuropathology and experimental neurology.
[5] G. C. Román,et al. Vascular dementia , 1993, Neurology.
[6] Karl J. Friston,et al. The Relationship between Global and Local Changes in PET Scans , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[7] A. Nordberg,et al. Age-dependent decline of neprilysin in Alzheimer's disease and normal brain: Inverse correlation with Aβ levels , 2008, Neurobiology of Aging.
[8] K. Davis,et al. Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease. , 1998, Archives of neurology.
[9] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[10] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[11] S. Folstein,et al. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.
[12] C. Rowe,et al. Imaging β-amyloid burden in aging and dementia , 2007, Neurology.
[13] Sanjiv S. Gambhir,et al. AMIDE: A Free Software Tool for Multimodality Medical Image Analysis , 2003 .
[14] Markus Schwaiger,et al. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer’s disease , 2008, NeuroImage.
[15] L. Jenkins,et al. Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD , 2005, Neurology.
[16] U Seligsohn,et al. Improved method for genotyping apolipoprotein E polymorphisms by a PCR-based assay simultaneously utilizing two distinct restriction enzymes. , 1997, Clinical chemistry.
[17] Nick C Fox,et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.
[18] Satoshi Minoshima,et al. Imaging Alzheimer's disease: clinical applications. , 2003, Neuroimaging clinics of North America.
[19] V. Libri,et al. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. , 2007, Brain : a journal of neurology.
[20] K. Davis,et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. , 2000, JAMA.
[21] H. Braak,et al. Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.
[22] S. DeKosky,et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[23] P. Hof,et al. Clinical Validity of Aß‐Protein Deposition Staging in Brain Aging and Alzheimer Disease , 2001 .
[24] R. Martínez-Murillo,et al. Intra- and extracellular Abeta and PHF in clinically evaluated cases of Alzheimer's disease. , 2004, Histology and histopathology.
[25] P. Hof,et al. Clinical validity of A beta-protein deposition staging in brain aging and Alzheimer disease. , 2001, Journal of neuropathology and experimental neurology.
[26] J. Price,et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. , 1998, Archives of neurology.
[27] L A Hansen,et al. The importance of neuritic plaques and tangles to the development and evolution of AD , 2004, Neurology.
[28] Brian J Cummings,et al. β-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease , 1996, Neurobiology of Aging.
[29] A. Monsch,et al. Normal ranges of neuropsychological tests for the diagnosis of Alzheimer's disease. , 2000, Studies in health technology and informatics.
[30] H. Engler,et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. , 2006, Brain : a journal of neurology.
[31] H. Engler,et al. PET imaging of amyloid deposition in patients with mild cognitive impairment , 2008, Neurobiology of Aging.
[32] Karl J. Friston,et al. Statistical parametric maps in functional imaging: A general linear approach , 1994 .
[33] N. Tzourio-Mazoyer,et al. Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain , 2002, NeuroImage.
[34] A. Drzezga,et al. Region-Specific Decline of Cerebral Glucose Metabolism in Patients with Frontotemporal Dementia: A Prospective 18F-FDG-PET Study , 2004, Dementia and Geriatric Cognitive Disorders.
[35] K. Davis,et al. Dissociation of neuropathology from severity of dementia in late-onset Alzheimer disease , 2006, Neurology.
[36] J. Morris,et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assesment of Alzheimer's disease , 1989, Neurology.